PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION28 March 2024, 08:00 a.m. CET
alfapump® – PMA1 submitted to US FDA and accepted for substantive review, extensive feedback...
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION18 October 2023, 07:00 am CEST First two US patients from non-randomized cohort successfully treated with DSR 2.0...
Ghent, Belgium – 6September2023– Sequana Medical NV(Euronext Brussels: SEQUA) (the "Company" or "SequanaMedical"), a pioneer in the treatment of fluid overload in liver disease,...
Ghent, Belgium – 22 March2023 – Sequana Medical NV(Euronext Brussels: SEQUA) (the "Company" or "SequanaMedical"), a pioneer in the treatment of fluid overload in liver...
Data from GLPi animal studies demonstrate safety of second-generation DSRii product (DSR 2.0) Data from Phase 1 studyof DSR 2.0 in Mexico (CHIHUAHUA)...
Ghent, Belgium – 2 February 2023– Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "SequanaMedical"), a pioneer in the treatment of fluid overload in...
Ghent, Belgium – 1 February 2023– Sequana Medical NV(Euronext Brussels: SEQUA) (the "Company" or "SequanaMedical"), a pioneer in the treatment of fluid overload in...
Carlyle has ended its 15-year ownership of aircraft engine and gas turbine specialist Sequa through a sale to fellow private equity house Veritas Capital.The...
